Mgc Diagnostics Corp (MGCD) 6.72 $MGCD
MGC Diagnostics Corporation to Report Third Quarter Fiscal Year 2016 Financial Results on Wednesday, September 7, 2016
PR Newswire - Wed Aug 31, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the third quarter fiscal year 2016, ended July 31, 2016. The call will be at 4:30 p.m. ET on Wednesday, September 7, 2016. The Company will report financial results for the third quarter fiscal year 2016 after the markets close on Wednesday, September 7, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Present at the 5th Annual InvestMNt Conference
PR Newswire - Tue Aug 09, 7:00AM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced that Todd Austin, Chief Executive Officer and Wes Winnekins, Chief Financial Officer, will present at the 5th Annual 2016 InvestMNt Conference on Wednesday, August 24, 2016 at 1:30 p.m. CT. The conference will be held at the University of St. Thomas in downtown Minneapolis, MN. The conference is sponsored by CFA Society of Minneapolis.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Announces Early Repayment of Debt
PR Newswire - Tue Jun 14, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced that it has paid off the remaining $2.5 million balance of its five-year, $4.0 million term loan and has terminated its revolving credit facility with BMO Harris Bank. The Company also announced it has resolved pending litigation with NeuroVirtual regarding a disputed distribution agreement.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal 2016 Second Quarter Results
PR Newswire - Wed Jun 01, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the second quarter ended April 30, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, June 1, 2016
PR Newswire - Tue May 24, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter fiscal year 2016, ended April 30, 2016. The call will be at 4:30 p.m. ET on Wednesday, June 1, 2016. The Company will report financial results for the second quarter fiscal year 2016 after the markets close on Wednesday, June 1, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal Year 2015 Financial Results
PR Newswire - Wed Jan 06, 3:01PM CST
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the fourth quarter and the fiscal year 2015, ended October 31, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Fourth Quarter and Fiscal Year 2015 Financial Results on Wednesday, January 6, 2016
PR Newswire - Thu Dec 17, 7:00AM CST
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2015, ended October 31, 2015. The call will be at 4:30 p.m. ET on Wednesday, January 6, 2016. The Company will report financial results for the fourth quarter and fiscal year 2015 after the markets close on Wednesday, January 6, 2016.
MGCD: 6.72 (+0.12)
Metabolic Testing Solutions - Global Strategic Business Report - Key Players are AEI Technologies, Bodystat, CareFusion, CORTEX Biophysik GmbH & COSMED
M2 - Fri Dec 04, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/klmhsw/metabolic_testing) has announced the addition of the "Metabolic Testing Solutions - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Metabolic Testing Solutions in US$ Thousand by the following Product Segments: ECGs/EKGs, Metabolic Carts, CPET Systems, and Others. The market is also analyzed by the following Technologies: VO2 Max Analysis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 91 companies including many key and niche players such as - - AEI Technologies, Inc. - Bodystat Limited - CareFusion Corporation - CORTEX Biophysik GmbH - COSMED Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS - AEI Technologies, Inc. (US) - Bodystat Limited (UK) - CareFusion Corporation (US) - CORTEX Biophysik GmbH (Germany) - COSMED (Italy) - GE Healthcare (UK) - Geratherm Medical AG (Germany) - Hologic, Inc. (US) - InBody Co., Ltd. (South Korea) - Iworx Systems, Inc. (US) - Jawon Medical Co. Ltd. (South Korea) - KORR Medical Technologies, Inc. (US) - Laica SpA (Italy) - MGC Diagnostics Corporation (US) - Microlife Medical Home Solutions, Inc. (US) - Mindray Medical International Limited (China) - Mortara Instrument, Inc. (US) - Nihon Kohden Corporation (Japan) - Noraxon U.S.A., Inc. (US) - Omron Healthcare, Inc. (US) - Parvo Medics (US) - Philips Healthcare (Netherlands) - RJL Systems, Inc. (US) - Schiller AG (Switzerland) - seca GmbH & Co. KG. (Germany) - Spacelabs Healthcare, Inc. (US) - Tanita Corporation (Japan) - Welch Allyn, Inc. (US) 7. GLOBAL MARKET PERSPECTIVE For more information visit http://www.researchandmarkets.com/research/kl...ic_testing
CFN: 59.91 (-0.06), MGCD: 6.72 (+0.12), MR: 27.94 (+0.07), HOLX: 38.46 (+0.04)
MGC Diagnostics Corporation Enters The Japanese Market By Establishing Partnership With Pacific-Medico
PR Newswire - Tue Nov 10, 7:00AM CST
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, today announced it has signed a multi-year partnership agreement with Pacific-Medico CO., LTD., Tokyo, Japan, to exclusively market MGC Diagnostics' CCM Express indirect calorimeter system in Japan.
MGCD: 6.72 (+0.12)
MGC Diagnostics Names Frederic Gavage Managing Director of Medisoft S.A.
PR Newswire - Mon Nov 02, 7:00AM CST
MGC Diagnostics (NASDAQ: MGCD), a global medical technology company, announced today that Frederic Gavage has been named Managing Director of MediSoft S.A., a wholly-owned subsidiary of MGC Diagnostics, effective immediately. Mr. Gavage will be responsible for the general management of MediSoft and will play a key role in the implementation of the Company's corporate strategy.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal 2015 Third Quarter Results
PR Newswire - Thu Sep 10, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the third quarter ended July 31, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015
PR Newswire - Tue May 26, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter of fiscal 2015, ended April 30, 2015. The call will be at 4:30 p.m. ET on Tuesday, June 2, 2015. The Company will report financial results for the second quarter of fiscal 2015 at the close of the markets on Tuesday, June 2, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Announces Newly Repackaged Ultima Series(TM)
PR Newswire - Wed May 13, 7:00AM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, announced today the release of its latest design of the Ultima Series TM cardiorespiratory diagnostic system, capable of performing both pulmonary function and metabolic testing in a single, modular, upgradeable platform, utilizing the latest technology. The system will be featured at the upcoming American Thoracic Society Meeting along with the full MGC Diagnostics Medical Graphics product line. Todd M. Austin, CEO of MGC Diagnostics, commented "This generation of MGC Diagnostic's Ultima Series TM, designed with both the patient and operator in mind, allows for maximum flexibility and operational efficiency, making it even easier to deliver cardiorespiratory diagnostic patient care with our intuitive, easy-to-use technology."
MGCD: 6.72 (+0.12)
Nasdaq stocks posting largest volume decreases
AP - Tue Apr 28, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
TSBK: 15.23 (+0.01), OPOF: 19.54 (-0.25), QADB: 20.18 (-0.02), ALOT: 14.93 (+0.20), HWBK: 14.19 (+0.10), WEBK: 21.84 (+0.14), QADA: 22.93 (-0.24), FCCO: 15.09 (+0.09), CHMG: 29.10 (-0.28), MGCD: 6.72 (+0.12), IKNX: 11.00 (-0.05)
Metabolic Testing Market by Product, by Application, by Technology, by End User - Global Forecast to 2019
M2 - Tue Mar 31, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncxgh5/metabolic_testing) has announced the addition of the "Metabolic Testing Market by Product (CPET, Body Composition Analysis, ECG, Portable System), by Application (Critical Care, Lifestyle Diseases), by Technology (REE, Body Composition Analysis), by End User (Gym, Sports, Hospital) - Global Forecast to 2019 " report to their offering. The global metabolic testing market is expected to reach $475.75 million by 2019 from $332.78 million in 2014, at a CAGR of 7.41% during the forecast period of 2014 to 2019. Metabolic testing equipment estimate the metabolic potential of an individual to determine their health and wellness. Metabolic testing equipment and software assist physicians and exercise physiologists to identify the risks of lifestyle disorders at an early stage and aid in the critical care of ICU patients. These equipments are also utilized in human performance testing for athletes and for commercial weight management programs. The lifestyle diseases segment accounted for the largest application segment of the metabolic testing market in 2014. In this report, the global metabolic testing market is segmented on the basis of products, technologies, applications, end users, and regions. The product segments of the market included in the report are CPET systems, metabolic carts, ECGs and EKGs, body composition analyzers, and software. The technology segments of the market included in the report are VO2 max analysis, RMR analysis, and body composition analysis. The application segments of the market included in the report are lifestyle diseases, critical care, human performance testing, dysmetabolic syndrome X, metabolic disorders, and other applications. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Metabolic Testing Market, By Product 8 Metabolic Testing Market, By Application 9 Metabolic Testing Market, By Technology 10 Metabolic Testing Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - AEI Technologies, Inc. - Carefusion Corporation - Cortex Biophysik GMBH - Cosmed - General Electric Company - Geratherm Medical AG - Korr Medical Technologies, Inc. - MGC Diagnostics Corporation - Microlife Medical Home Solutions, Inc. - OSI Systems, Inc. - Parvo Medics For more information visit http://www.researchandmarkets.com/research/nc...ic_testing
GE: 31.20 (-0.04), MGCD: 6.72 (+0.12), OSIS: 67.55 (+0.49)
MGC Diagnostics Corporation to Report Third Quarter Fiscal Year 2016 Financial Results on Wednesday, September 7, 2016
PR Newswire - Wed Aug 31, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the third quarter fiscal year 2016, ended July 31, 2016. The call will be at 4:30 p.m. ET on Wednesday, September 7, 2016. The Company will report financial results for the third quarter fiscal year 2016 after the markets close on Wednesday, September 7, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Present at the 5th Annual InvestMNt Conference
PR Newswire - Tue Aug 09, 7:00AM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced that Todd Austin, Chief Executive Officer and Wes Winnekins, Chief Financial Officer, will present at the 5th Annual 2016 InvestMNt Conference on Wednesday, August 24, 2016 at 1:30 p.m. CT. The conference will be held at the University of St. Thomas in downtown Minneapolis, MN. The conference is sponsored by CFA Society of Minneapolis.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Announces Early Repayment of Debt
PR Newswire - Tue Jun 14, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced that it has paid off the remaining $2.5 million balance of its five-year, $4.0 million term loan and has terminated its revolving credit facility with BMO Harris Bank. The Company also announced it has resolved pending litigation with NeuroVirtual regarding a disputed distribution agreement.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal 2016 Second Quarter Results
PR Newswire - Wed Jun 01, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the second quarter ended April 30, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, June 1, 2016
PR Newswire - Tue May 24, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter fiscal year 2016, ended April 30, 2016. The call will be at 4:30 p.m. ET on Wednesday, June 1, 2016. The Company will report financial results for the second quarter fiscal year 2016 after the markets close on Wednesday, June 1, 2016.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal Year 2015 Financial Results
PR Newswire - Wed Jan 06, 3:01PM CST
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the fourth quarter and the fiscal year 2015, ended October 31, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Fourth Quarter and Fiscal Year 2015 Financial Results on Wednesday, January 6, 2016
PR Newswire - Thu Dec 17, 7:00AM CST
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2015, ended October 31, 2015. The call will be at 4:30 p.m. ET on Wednesday, January 6, 2016. The Company will report financial results for the fourth quarter and fiscal year 2015 after the markets close on Wednesday, January 6, 2016.
MGCD: 6.72 (+0.12)
Metabolic Testing Solutions - Global Strategic Business Report - Key Players are AEI Technologies, Bodystat, CareFusion, CORTEX Biophysik GmbH & COSMED
M2 - Fri Dec 04, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/klmhsw/metabolic_testing) has announced the addition of the "Metabolic Testing Solutions - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Metabolic Testing Solutions in US$ Thousand by the following Product Segments: ECGs/EKGs, Metabolic Carts, CPET Systems, and Others. The market is also analyzed by the following Technologies: VO2 Max Analysis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 91 companies including many key and niche players such as - - AEI Technologies, Inc. - Bodystat Limited - CareFusion Corporation - CORTEX Biophysik GmbH - COSMED Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS - AEI Technologies, Inc. (US) - Bodystat Limited (UK) - CareFusion Corporation (US) - CORTEX Biophysik GmbH (Germany) - COSMED (Italy) - GE Healthcare (UK) - Geratherm Medical AG (Germany) - Hologic, Inc. (US) - InBody Co., Ltd. (South Korea) - Iworx Systems, Inc. (US) - Jawon Medical Co. Ltd. (South Korea) - KORR Medical Technologies, Inc. (US) - Laica SpA (Italy) - MGC Diagnostics Corporation (US) - Microlife Medical Home Solutions, Inc. (US) - Mindray Medical International Limited (China) - Mortara Instrument, Inc. (US) - Nihon Kohden Corporation (Japan) - Noraxon U.S.A., Inc. (US) - Omron Healthcare, Inc. (US) - Parvo Medics (US) - Philips Healthcare (Netherlands) - RJL Systems, Inc. (US) - Schiller AG (Switzerland) - seca GmbH & Co. KG. (Germany) - Spacelabs Healthcare, Inc. (US) - Tanita Corporation (Japan) - Welch Allyn, Inc. (US) 7. GLOBAL MARKET PERSPECTIVE For more information visit http://www.researchandmarkets.com/research/kl...ic_testing
CFN: 59.91 (-0.06), MGCD: 6.72 (+0.12), MR: 27.94 (+0.07), HOLX: 38.46 (+0.04)
MGC Diagnostics Corporation Enters The Japanese Market By Establishing Partnership With Pacific-Medico
PR Newswire - Tue Nov 10, 7:00AM CST
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, today announced it has signed a multi-year partnership agreement with Pacific-Medico CO., LTD., Tokyo, Japan, to exclusively market MGC Diagnostics' CCM Express indirect calorimeter system in Japan.
MGCD: 6.72 (+0.12)
MGC Diagnostics Names Frederic Gavage Managing Director of Medisoft S.A.
PR Newswire - Mon Nov 02, 7:00AM CST
MGC Diagnostics (NASDAQ: MGCD), a global medical technology company, announced today that Frederic Gavage has been named Managing Director of MediSoft S.A., a wholly-owned subsidiary of MGC Diagnostics, effective immediately. Mr. Gavage will be responsible for the general management of MediSoft and will play a key role in the implementation of the Company's corporate strategy.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Reports Fiscal 2015 Third Quarter Results
PR Newswire - Thu Sep 10, 3:01PM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the third quarter ended July 31, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015
PR Newswire - Tue May 26, 7:00AM CDT
MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter of fiscal 2015, ended April 30, 2015. The call will be at 4:30 p.m. ET on Tuesday, June 2, 2015. The Company will report financial results for the second quarter of fiscal 2015 at the close of the markets on Tuesday, June 2, 2015.
MGCD: 6.72 (+0.12)
MGC Diagnostics Corporation Announces Newly Repackaged Ultima Series(TM)
PR Newswire - Wed May 13, 7:00AM CDT
MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, announced today the release of its latest design of the Ultima Series TM cardiorespiratory diagnostic system, capable of performing both pulmonary function and metabolic testing in a single, modular, upgradeable platform, utilizing the latest technology. The system will be featured at the upcoming American Thoracic Society Meeting along with the full MGC Diagnostics Medical Graphics product line. Todd M. Austin, CEO of MGC Diagnostics, commented "This generation of MGC Diagnostic's Ultima Series TM, designed with both the patient and operator in mind, allows for maximum flexibility and operational efficiency, making it even easier to deliver cardiorespiratory diagnostic patient care with our intuitive, easy-to-use technology."
MGCD: 6.72 (+0.12)
Nasdaq stocks posting largest volume decreases
AP - Tue Apr 28, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
TSBK: 15.23 (+0.01), OPOF: 19.54 (-0.25), QADB: 20.18 (-0.02), ALOT: 14.93 (+0.20), HWBK: 14.19 (+0.10), WEBK: 21.84 (+0.14), QADA: 22.93 (-0.24), FCCO: 15.09 (+0.09), CHMG: 29.10 (-0.28), MGCD: 6.72 (+0.12), IKNX: 11.00 (-0.05)
Metabolic Testing Market by Product, by Application, by Technology, by End User - Global Forecast to 2019
M2 - Tue Mar 31, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncxgh5/metabolic_testing) has announced the addition of the "Metabolic Testing Market by Product (CPET, Body Composition Analysis, ECG, Portable System), by Application (Critical Care, Lifestyle Diseases), by Technology (REE, Body Composition Analysis), by End User (Gym, Sports, Hospital) - Global Forecast to 2019 " report to their offering. The global metabolic testing market is expected to reach $475.75 million by 2019 from $332.78 million in 2014, at a CAGR of 7.41% during the forecast period of 2014 to 2019. Metabolic testing equipment estimate the metabolic potential of an individual to determine their health and wellness. Metabolic testing equipment and software assist physicians and exercise physiologists to identify the risks of lifestyle disorders at an early stage and aid in the critical care of ICU patients. These equipments are also utilized in human performance testing for athletes and for commercial weight management programs. The lifestyle diseases segment accounted for the largest application segment of the metabolic testing market in 2014. In this report, the global metabolic testing market is segmented on the basis of products, technologies, applications, end users, and regions. The product segments of the market included in the report are CPET systems, metabolic carts, ECGs and EKGs, body composition analyzers, and software. The technology segments of the market included in the report are VO2 max analysis, RMR analysis, and body composition analysis. The application segments of the market included in the report are lifestyle diseases, critical care, human performance testing, dysmetabolic syndrome X, metabolic disorders, and other applications. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Metabolic Testing Market, By Product 8 Metabolic Testing Market, By Application 9 Metabolic Testing Market, By Technology 10 Metabolic Testing Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - AEI Technologies, Inc. - Carefusion Corporation - Cortex Biophysik GMBH - Cosmed - General Electric Company - Geratherm Medical AG - Korr Medical Technologies, Inc. - MGC Diagnostics Corporation - Microlife Medical Home Solutions, Inc. - OSI Systems, Inc. - Parvo Medics For more information visit http://www.researchandmarkets.com/research/nc...ic_testing
GE: 31.20 (-0.04), MGCD: 6.72 (+0.12), OSIS: 67.55 (+0.49)
